Insider Transactions in Q1 2023 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
176
-2.41%
|
$55,088
$313.74 P/Share
|
|
Mar 31
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-2.98%
|
$458,858
$313.74 P/Share
|
|
Mar 24
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.44%
|
$539,240
$305.38 P/Share
|
|
Mar 17
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-0.63%
|
$594,000
$297.51 P/Share
|
|
Mar 16
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,746
-2.65%
|
$823,800
$300.81 P/Share
|
|
Mar 13
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,666
-0.81%
|
$781,138
$293.54 P/Share
|
|
Mar 10
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,088
-0.46%
|
$605,520
$290.69 P/Share
|
|
Feb 27
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
354
-0.21%
|
$101,952
$288.27 P/Share
|
|
Feb 27
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,207
-4.85%
|
$347,616
$288.52 P/Share
|
|
Feb 27
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,034
-2.77%
|
$1,444,758
$287.89 P/Share
|
|
Feb 27
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,238
-3.96%
|
$1,220,544
$288.52 P/Share
|
|
Feb 24
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-5.47%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-5.38%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
3,970
-7.09%
|
$1,147,330
$289.12 P/Share
|
|
Feb 24
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,730
-22.12%
|
$3,967,970
$289.12 P/Share
|
|
Feb 24
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,468
-3.58%
|
$713,252
$289.12 P/Share
|
|
Feb 24
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-4.97%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,386
-6.74%
|
$2,712,554
$289.12 P/Share
|
|
Feb 24
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
502
-5.57%
|
$145,078
$289.12 P/Share
|
|
Feb 24
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,714
-7.11%
|
$1,362,346
$289.12 P/Share
|
|
Feb 24
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,970
-9.86%
|
$1,147,330
$289.12 P/Share
|
|
Feb 22
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
2,401
-0.71%
|
$705,894
$294.14 P/Share
|
|
Feb 21
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
480
-0.2%
|
$140,640
$293.11 P/Share
|
|
Feb 21
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
2,402
-0.85%
|
$703,786
$293.02 P/Share
|
|
Feb 21
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,002
-2.33%
|
$1,172,586
$293.13 P/Share
|
|
Feb 17
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-6.28%
|
$1,095,000
$292.85 P/Share
|
|
Feb 17
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,498
-6.87%
|
$1,313,416
$292.85 P/Share
|
|
Feb 17
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-5.75%
|
$1,095,000
$292.85 P/Share
|
|
Feb 17
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,498
-4.83%
|
$1,021,416
$292.85 P/Share
|
|
Feb 17
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,359
-6.29%
|
$2,732,828
$292.85 P/Share
|
|
Feb 17
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,498
-5.95%
|
$1,313,416
$292.85 P/Share
|
|
Feb 17
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-5.34%
|
$1,095,000
$292.85 P/Share
|
|
Feb 17
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-7.81%
|
$1,095,000
$292.85 P/Share
|
|
Feb 14
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
320
-0.1%
|
$95,360
$298.11 P/Share
|
|
Feb 14
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,181
-1.77%
|
$654,300
$300.7 P/Share
|
|
Feb 14
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,398
-2.05%
|
$1,906,604
$298.47 P/Share
|
|
Feb 14
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
6,398
-1.34%
|
$1,906,604
$298.49 P/Share
|
|
Feb 13
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,992
-7.11%
|
$1,487,616
$298.26 P/Share
|
|
Feb 13
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
275
-0.08%
|
$81,950
$298.72 P/Share
|
|
Feb 13
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,995
-4.34%
|
$892,510
$298.26 P/Share
|
|
Feb 13
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
4,657
-6.04%
|
$1,387,786
$298.26 P/Share
|
|
Feb 13
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
113
-0.18%
|
$33,900
$300.39 P/Share
|
|
Feb 13
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
4,340
-6.54%
|
$1,293,320
$298.26 P/Share
|
|
Feb 13
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,344
-17.69%
|
$3,976,512
$298.26 P/Share
|
|
Feb 13
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,798
-2.08%
|
$1,429,804
$298.63 P/Share
|
|
Feb 13
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,990
-9.19%
|
$1,785,020
$298.26 P/Share
|
|
Feb 13
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
4,887
-1.43%
|
$1,456,326
$298.56 P/Share
|
|
Feb 13
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,990
-6.45%
|
$1,785,020
$298.26 P/Share
|
|
Feb 13
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,992
-6.63%
|
$1,487,616
$298.26 P/Share
|
|
Feb 13
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,990
-3.87%
|
$1,785,020
$298.26 P/Share
|